Patient and Provider Perspectives on Benefits and Harms of Continuing, Tapering, and Discontinuing Long-Term Opioid Therapy

被引:9
|
作者
Nevedal, Andrea L. [1 ]
Timko, Christine [2 ,3 ]
Lor, Mai Chee [2 ]
Hoggatt, Katherine J. [4 ,5 ]
机构
[1] VA Ctr Clin Management Res, Dept Vet Affairs Hlth Care Syst, Ann Arbor, MI 48105 USA
[2] Ctr Innovat Implementat, Dept Vet Affairs Hlth Care Syst, Palo Alto, CA USA
[3] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA
[4] San Francisco VA Hlth Care Syst, San Francisco, CA USA
[5] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA
关键词
opioids; tapering; veterans; patients; providers; qualitative methods; long-term opioid therapy; COMPLEMENTARY;
D O I
10.1007/s11606-022-07880-z
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background Given efforts to taper patients off long-term opioid therapy (LTOT) because of known harms, it is important to understand if patients and providers align in LTOT treatment goals. Objective To investigate patient and provider perceptions about the harms and benefits of continuing and discontinuing LTOT. Design Qualitative study Participants Patients and providers with experiences with LTOT for pain in two Veterans Health Affairs regions. Approach We conducted semi-structured interviews and analyzed data using rapid qualitative analysis to describe patient and provider preferences about LTOT continuation and discontinuation and non-opioid pain treatments. Key Results Participants (n=43) included 28/67 patients and 15/17 providers. When discussing continuing LTOT, patients emphasized the benefits outweighed the harms, whereas providers emphasized the harms. Participants agreed on the benefits of continuing LTOT for improved physical functioning. Provider-reported benefits of continuing LTOT included maintaining the status quo for patients without opioid alternatives or who were at risk for illicit drug use. Participants were aligned regarding the harms of negative side-effects (e.g., constipation) from continued LTOT. In contrast, when discussing LTOT tapering and discontinuation, providers underscored how benefits outweighed the harms, citing patients' improved well-being and pain management with tapering or alternatives. Patients did not foresee benefits to potential LTOT tapers or discontinuation and were worried about pain management in the absence of LTOT. When discussing non-opioid pain treatments, participants emphasized that they were adjunctive to opioid therapy rather than a replacement (except for cannabis). Providers described the importance of mental health services to manage pain, which differed from patients who focused on treatments to improve strength and mobility and reduce pain. Conclusions Patients emphasized the benefits of continuing LTOT for pain management and well-being, which differed from providers' emphasis on the benefits of discontinuing LTOT. Patient and provider differences are important for informing patient-centered care and decisions around continuing, tapering, or discontinuing LTOT.
引用
收藏
页码:1802 / 1811
页数:10
相关论文
共 50 条
  • [31] Comparing Patient and Provider Perspectives on Long Term Biologic Use and Tapering in Stable, Well-Controlled Rheumatoid Arthritis
    Webster, Patrick
    Wilson, Nicole
    Payne, Christina
    Shields, Kelly
    Sharma, Tarun
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [32] Clinical outcomes of discontinuing long-term opioid therapy among older cancer survivors in nursing homes
    Wei, Yu-Jung Jenny
    Winterstein, Almut G.
    Schmidt, Siegfried
    Fillingim, Roger B.
    Daniels, Michael
    DeKosky, Steven T.
    Kinder, Ben
    Cheng, Ting-Yuan David
    CANCER RESEARCH, 2024, 84 (06)
  • [33] Clinical Outcomes of Discontinuing Long-Term Opioid Therapy Among Older Cancer Survivors in Nursing Homes
    Wei, Yu-Jung Jenny
    Winterstein, Almut G.
    Schmidt, Siegfried
    Fillingim, Roger
    Daniels, Michael J.
    Schmidt, Stephan
    DeKosky, Steven
    Kinder, Ben
    Cheng, Ting-Yuan David
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 568 - 568
  • [34] Patient Experiences With Buprenorphine Following Discontinuation of Long-Term Opioid Therapy
    Wyse, Jessica
    Ono, Sarah
    Zaccari, Belle
    Lovejoy, Jennette
    Jacobson, Noah
    Gulati, Ayushi
    Wu, Tiona
    Levine, Taylor
    Goerlich, Amie
    Lovejoy, Travis
    DRUG AND ALCOHOL DEPENDENCE, 2024, 260
  • [35] In the balance: No new diagnosis needed in addition to opioid use disorder to study harms associated with long-term opioid therapy
    Drexler, Karen
    Edens, Ellen L.
    Trafton, Jodie A.
    Compton, Wilson M.
    ADDICTION, 2024, 119 (01) : 6 - 8
  • [36] Initial Feasibility of a Randomized Controlled Trial for Long-Term Opioid Therapy Tapering via the Summit Program
    Schneider, Victor J., II
    Wesolowicz, Danielle M.
    Moore, Brent
    Becker, William C.
    Edmond, Sara N.
    JOURNAL OF PAIN, 2024, 25 (04): : 71 - 71
  • [37] Long-Term Opioid Therapy Reconsidered
    Von Korff, Michael
    Kolodny, Andrew
    Deyo, Richard A.
    Chou, Roger
    ANNALS OF INTERNAL MEDICINE, 2011, 155 (05) : 325 - 328
  • [38] Benzodiazepines in Long-Term Opioid Therapy
    Reisfield, Gary M.
    Webster, Lynn R.
    PAIN MEDICINE, 2013, 14 (10) : 1441 - 1446
  • [39] CRITERIA FOR DISCONTINUING NEONATAL SEIZURE THERAPY - A LONG-TERM APPRAISAL
    SCARPA, P
    CHIERICI, R
    TAMISARI, L
    FORTINI, C
    VOLPATO, S
    BRAIN & DEVELOPMENT, 1983, 5 (06): : 541 - 548
  • [40] Discontinuing Long-Term PPI Therapy: Why, With Whom, and How?
    Targownik, Laura
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 (04): : 519 - 528